Text Size

Impact of P-glycoprotein on blood-retinal barrier permeability: Comparison of blood-aqueous humor and blood-brain barrier using mdr1a knockout rats

Fujii S., Setoguchi C., Kawazu K., Hosoya K.-I.


  • 2014
  • Investigative Ophthalmology and Visual Science
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Preclinical development

  • Affiliations

    Nara Research and Development Center, Santen Pharmaceutical Co., Ltd., Nara, Japan; Department of Pharmaceutics, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama, Japan

Related Publications

The growing burden of myopia in Europe: evidence from population-based cohorts

Tiemens A., van Hemert D.J., Lemma S.T., Quist S.W., Shi-van Wielink K., Agius D., Arnould L., Berendschot T.T.J.M., Beuse A., Bikbov M.M., Birtel J., Bountziouka V., Breteler M.M.B., Carbonaro F., Chakravarthy U., Coimbra R., de Vries V.A., Delcourt C., Farinha C., Finger R.P., Ghanbari M., Giannoulis D.A., Grohmann C., Hammond C.J., European Eye Epidemiology (E3) Consortium


Low-Dose Atropine and Other Interventions for Pediatric Myopia: A Systematic Review and Bayesian Network Meta-analysis of Efficacy and Post-treatment Outcomes

Jovanović J., Zacharioudaki M., Kalatzi M., Papadakis G., Mulkalapalli N., Ernst F., de Milliano T.


Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective

Shi-van Wielink K., Dahlmann-Noor A., Li J., de Milliano T.W.L., Ernst F., Croci F., Sharma Y., Punekar Y.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022